Sleepwalking research has advanced significantly in recent years, reshaping how scientists understand why some brains walk while the rest of the body should be asleep. The biggest shifts involve brain imaging that reveals a split between sleeping and waking brain regions, genetic markers that predict vulnerability, links to Parkinson’s disease, and the first structured behavioral therapies shown to dramatically reduce episodes. About 6.9% of people will sleepwalk at some point in their lives, with roughly 5% of children and 1.5% of adults experiencing an episode in any given year.
Your Brain Is Half Awake and Half Asleep
The most important concept to emerge from recent neuroimaging research is “sleep-wake dissociation,” the idea that during a sleepwalking episode, parts of your brain are genuinely awake while other parts remain locked in deep sleep. This isn’t a metaphor. Brain scans confirm it.
During an episode, the motor cortex (which controls movement) and a region called the anterior cingulate cortex (involved in motivation and basic decision-making) light up with wake-like electrical activity. Meanwhile, the frontal and parietal association areas, the regions responsible for judgment, self-awareness, and complex reasoning, stay submerged in slow-wave sleep. A systematic review of brain imaging studies in NREM parasomnias confirmed that these anterior cingulate and frontal-medial areas consistently show activation while the rest of the cortex remains asleep.
This explains the strange hallmark of sleepwalking: the person can navigate a room, open doors, even carry on a rudimentary conversation, yet has no conscious awareness or memory of it. The parts of the brain needed for physical movement are online. The parts needed for knowing who you are and what you’re doing are not. Researchers now describe sleepwalking not as a disorder of sleep itself, but as a failure of the brain to fully transition between sleep and wakefulness.
Genetics Play a Larger Role Than Expected
Sleepwalking runs in families, and the numbers are striking. About 42% of people with NREM parasomnias (the broader category that includes sleepwalking, sleep terrors, and confusional arousals) report a first-degree relative with the same problem. If one of your parents sleepwalked, your risk is substantially higher than the general population.
Researchers have identified specific genetic markers tied to this vulnerability. A gene variant called HLA DQB1*05:01, part of the immune system’s human leukocyte antigen complex, appears in 41% of parasomnia patients compared to about 24% of the general population. This association holds across different types of NREM parasomnias, not just sleepwalking alone. A separate genome-wide study of a single large family with 22 sleepwalkers traced significant genetic linkage to a region on chromosome 20.
The involvement of immune-related genes is intriguing because it hints that sleepwalking may share biological pathways with autoimmune and inflammatory processes, though the exact mechanism connecting HLA genes to arousal instability during sleep remains unclear.
Sleep Medications Can Trigger Episodes
In 2019, the FDA added its strongest safety warning (a boxed warning) to three widely prescribed insomnia medications after reports of serious injuries during sleepwalking episodes. The drugs are zolpidem (sold as Ambien), eszopiclone (Lunesta), and zaleplon (Sonata). All three belong to a class of sedative-hypnotics that work by slowing brain activity to induce sleep.
Of the cases the FDA reviewed, the vast majority involved zolpidem, with 61 reported cases compared to just 3 for eszopiclone and 2 for zaleplon. These weren’t minor events. Patients drove cars, walked into traffic, and sustained serious injuries, all with no memory of the behavior. The warning now states that anyone who has experienced a complex sleep behavior on one of these medications should not take them again. This is particularly relevant for people who already have a personal or family history of sleepwalking, since the medications appear to lower the arousal threshold in a brain already prone to incomplete waking.
A Possible Link to Parkinson’s Disease
One of the more surprising recent findings comes from a cross-sectional study of nearly 26,000 men in the Health Professionals Follow-up Study. Researchers found that men who reported probable sleepwalking had nearly five times the odds of also having Parkinson’s disease compared to men without sleep parasomnias. When sleepwalking co-occurred with another parasomnia called REM sleep behavior disorder (where people physically act out dreams), the odds jumped to more than eight times higher.
This doesn’t mean sleepwalking causes Parkinson’s or that sleepwalkers should panic. The study was cross-sectional, meaning it captured a snapshot in time and can’t establish which came first. The leading interpretation is that the same neurodegenerative changes that cause Parkinson’s may also disrupt the brain’s ability to regulate transitions between sleep states. In other words, sleepwalking in older adults could be a symptom of underlying neurological changes rather than a cause. Prospective studies tracking people over time are still needed to clarify the relationship, but the finding has opened a new line of investigation into sleep parasomnias as potential early signals of brain changes.
Behavioral Therapy Now Has Real Evidence
For years, treatment options for sleepwalking were limited to vague sleep hygiene advice or off-label medications. That’s beginning to change. A structured cognitive behavioral therapy program designed specifically for parasomnias (called CBTp) has shown striking results in clinical testing. The six-week program combines education about sleep architecture, relaxation techniques, specific parasomnia-targeted strategies, and relapse prevention planning.
In a controlled study, participants who completed CBTp dropped from an average of about 5.5 parasomnia episodes per week to just over 1 episode per week. The control group, which only self-monitored their symptoms, saw no improvement at all, actually averaging slightly more episodes by the end of the study. The improvements held at follow-up, and 100% of treated participants rated themselves as improved. Beyond reducing episodes, the therapy also lowered distress ratings and improved overall sleep quality. By the end of treatment, 75% of the therapy group had sleep that met normative standards for total sleep time, how quickly they fell asleep, and how often they woke during the night.
These are small studies, and the therapy isn’t yet widely available. But the results represent the first solid evidence that a non-drug approach can meaningfully reduce sleepwalking frequency and severity.
Practical Safety Still Matters
While research advances, the immediate priority for people who sleepwalk regularly is physical safety. Sleep specialists recommend removing sharp objects, glass items, and furniture with hard edges from the bedroom. For children who sleepwalk, bunk beds should be avoided. Locking doors and windows prevents sleepwalkers from leaving the house, and installing gates at the top of staircases reduces the risk of falls.
These measures are simple but genuinely important. Most sleepwalking injuries happen from collisions with furniture, falls down stairs, or leaving the home and encountering traffic or uneven ground. A sleepwalker’s motor system is functional enough to walk but not coordinated or aware enough to recognize danger. Making the environment forgiving of clumsy, unconscious navigation is the single most effective thing a household can do while longer-term management strategies are explored.